Publications by authors named "O Sommerburg"
Article Synopsis
- Segmentation of lung structures in medical imaging is important for diagnosing and treating diseases like cystic fibrosis, with neural networks showing better results than traditional methods, but challenges remain with different imaging types and pathologies.
- This study used deep learning to segment MRI scans from pediatric cystic fibrosis patients, employing the nnU-Net framework and analyzing data from 165 scans across various sequences (BLADE, VIBE, HASTE). The analysis focused on patient variability in disease severity and age.
- Results indicated high segmentation accuracy (with Dice coefficients around 0.95-0.96) and consistent performance regardless of patient differences, although some issues with segmentation completeness were noted, particularly in the diaphragm area; the model also showed
Background/objectives: Elexacaftor, tezacaftor, and ivacaftor (ETI) have significantly improved lung function in people with cystic fibrosis (pwCF). Despite exceptional improvements in most cases, treatment-related inter-subject variability and drug-drug interactions that complicate modulator therapy have been reported.
Methods: This retrospective analysis presents data on the serum concentration of ETI in our pwCF with full or reduced dosage from August 2021 to December 2023 via routine therapeutic drug monitoring (TDM).
Rationale: The progression of lung changes in cystic fibrosis (CF) from infancy through adolescence remains poorly understood due to limited longitudinal imaging data.
Objectives: To assess changes in lung morphology and perfusion in children with CF through the pediatric age range by longitudinal chest magnetic resonance imaging (MRI).
Methods: 1112 annual chest MRI were performed in 226 patients with CF aged 0-18yr.
Clinical trials show that lumacaftor/ivacaftor (LUM/IVA) treatment has the potential to modify early cystic fibrosis (CF) disease progression in children as young as 2 years of age. To assess the long-term impact of LUM/IVA treatment on CF disease progression in children aged 2-5 years. This phase 2 trial had two parts: part 1, a 48-week, randomized, double-blind, placebo-controlled study of LUM/IVA in children aged 2-5 years (previously reported) was followed by a 48-week open-label treatment period in which all children received LUM/IVA (part 2; reported here).
View Article and Find Full Text PDFArticle Synopsis
- - The study investigated the impact of elexacaftor/tezacaftor/ivacaftor (ETI) on lung health in school-age children (ages 6-11) with cystic fibrosis (CF), specifically looking at lung clearance index (LCI) and lung MRI scores over a year.
- - A total of 107 children participated, showing significant improvements in LCI and MRI scores three months after starting ETI, with better results for both heterozygous and homozygous mutations.
- - The findings suggest that early treatment with ETI can enhance lung function and structure, potentially slowing down lung disease progression in children with CF.